”Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions you may have regarding a medical condition.
You've probably seen the headlines: "Game-changing weight loss drug," "Diabetes shot melts pounds away," "Ozempic shortage."
GLP-1 receptor agonists have transformed diabetes treatment and weight management. The 2025 ADA guidelines now recommend them as first-line options for many patients with type 2 diabetes.
But what are these medications? How do they work? And which one might be right for you?
What Are GLP-1 Agonists?
The Science
GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut that:
- Stimulates insulin secretion when blood sugar rises
- Suppresses glucagon (a hormone that raises blood sugar)
- Slows gastric emptying (food stays in stomach longer)
- Signals fullness to the brain
GLP-1 agonists mimic this natural hormone, providing these effects in a stronger, longer-lasting way.
How GLP-1 Agonists Work
| Action | Effect |
|---|---|
| Increases insulin secretion | Lowers blood sugar after meals |
| Decreases glucagon secretion | Reduces liver glucose production |
| Slows stomach emptying | Increases fullness, reduces appetite |
| Acts on brain hunger centers | Reduces food intake |
| May improve cardiovascular health | Reduces cardiovascular events |
Available GLP-1 Agonists
Short-Acting (Twice Daily)
| Medication | Dosing | A1C Reduction | Weight Loss |
|---|---|---|---|
| Exenatide (Byetta) | Twice daily before meals | 0.8-1.0% | 2-3 kg |
| Lixisenatide (not available in US) | Twice daily | 0.5-0.8% | 2 kg |
Long-Acting (Once Weekly or Once Daily)
| Medication | Dosing | A1C Reduction | Weight Loss | Cardiovascular Benefit |
|---|---|---|---|---|
| Exenatide XR (Bydureon) | Weekly | 1.0-1.3% | 2-3 kg | Neutral |
| Dulaglutide (Trulicity) | Weekly | 1.0-1.5% | 3-5 kg | Yes (REWIND trial) |
| Semaglutide injection (Ozempic) | Weekly | 1.0-1.8% | 5-8 kg | Yes (SUSTAIN-6) |
| Semaglutide oral (Rybelsus) | Daily | 1.0-1.4% | 2-4 kg | Being studied |
| Liraglutide (Victoza) | Daily | 1.0-1.5% | 3-4 kg | Yes (LEADER trial) |
Dual GIP/GLP-1 Agonist
| Medication | Dosing | A1C Reduction | Weight Loss | Cardiovascular Benefit |
|---|---|---|---|---|
| Tirzepatide (Mounjaro) | Weekly | 1.8-2.6% | 7-12+ kg | Yes (SURPASS) |
Head-to-Head Comparison
A1C Reduction
| Most Effective | → | → | → | → | Least Effective |
|---|---|---|---|---|---|
| Tirzepatide | Semaglutide | Dulaglutide | Liraglutide | Exenatide XR | Exenatide (twice daily) |
Weight Loss
| Most Effective | → | → | → | → | Least Effective |
|---|---|---|---|---|---|
| Tirzepatide | Semaglutide | Dulaglutide | Liraglutide | Exenatide XR | Exenatide (twice daily) |
Convenience
| Most Convenient | → | → | → | Least Convenient |
|---|---|---|---|---|
| Weekly injections | Weekly injections | Daily oral | Daily injection | Twice daily injection |
Individual Medications
Semaglutide (Ozempic)
What it is: Weekly GLP-1 injection approved for type 2 diabetes
Key features:
- Dose: 0.25 mg → 0.5 mg → 1 mg → 2 mg (max)
- Administration: Weekly subcutaneous injection
- A1C reduction: Up to 1.8%
- Weight loss: Average 5-8 kg (up to 15 kg in some studies)
- Cardiovascular benefit: Proven (SUSTAIN-6 trial: 26% reduction in MACE)
- Side effects: Nausea (most common), vomiting, diarrhea, constipation
Best for: Patients needing significant A1C reduction and weight loss, especially with cardiovascular disease
Dulaglutide (Trulicity)
What it is: Weekly GLP-1 injection approved for type 2 diabetes
Key features:
- Dose: 0.75 mg → 1.5 mg → 3 mg → 4.5 mg (max)
- Administration: Weekly subcutaneous injection (comes in easy-use pen)
- A1C reduction: Up to 1.5%
- Weight loss: Average 3-5 kg
- Cardiovascular benefit: Proven (REWIND trial: 12% reduction in MACE)
- Side effects: Nausea (generally less than semaglutide), diarrhea, abdominal pain
Best for: Patients who want weekly injection with potentially fewer GI side effects
Liraglutide (Victoza)
What it is: Daily GLP-1 injection approved for type 2 diabetes (and obesity at higher dose as Saxenda)
Key features:
- Dose: 0.6 mg → 1.2 mg → 1.8 mg daily (max 1.8 mg for diabetes)
- Administration: Daily subcutaneous injection
- A1C reduction: Up to 1.5%
- Weight loss: Average 3-4 kg
- Cardiovascular benefit: Proven (LEADER trial: 13% reduction in cardiovascular death)
- Side effects: Nausea, vomiting, diarrhea
Best for: Patients who prefer daily dosing (to titrate more gradually) or those transitioning to Saxenda for weight
Tirzepatide (Mounjaro)
What it is: Dual GIP/GLP-1 receptor agonist approved for type 2 diabetes
Key features:
- Dose: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (max)
- Administration: Weekly subcutaneous injection
- A1C reduction: Up to 2.6% (highest of any diabetes medication)
- Weight loss: Average 7-12 kg (up to 20+ kg in studies)
- Cardiovascular benefit: Proven (SURPASS-CVO trial)
- Side effects: Nausea (can be significant at higher doses), vomiting, diarrhea
Best for: Patients needing maximal A1C reduction and weight loss, especially those with high BMI
Side Effects
Common Side Effects
| Side Effect | Frequency | Management |
|---|---|---|
| Nausea | 20-40% | Start low, go slow; eat smaller meals; avoid high-fat foods |
| Vomiting | 10-20% | Stay hydrated; temporary during titration |
| Diarrhea | 10-15% | Stay hydrated; avoid high-fat, spicy foods |
| Constipation | 5-10% | Increase fiber, fluids, physical activity |
| Abdominal pain | 5-10% | Usually improves with time |
| Headache | 5-10% | OTC pain relievers if needed |
| Fatigue | 5% | Usually temporary |
Strategies to Minimize GI Side Effects
- Start at the lowest dose and increase gradually
- Eat smaller, more frequent meals
- Avoid high-fat, spicy foods during titration
- Stay hydrated
- Give it time—side effects typically improve within 4-8 weeks
Rare but Serious Side Effects
| Concern | Risk | Who Should Avoid |
|---|---|---|
| Pancreatitis | Very rare | History of pancreatitis |
| Gallbladder disease | Slightly increased | Existing gallstones |
| Medullary thyroid cancer | Theoretical (animal studies) | Personal/family history of MTC |
| Multiple endocrine neoplasia type 2 | Theoretical | Genetic syndrome |
Cardiovascular Benefits
Why This Matters
GLP-1 agonists (except exenatide) have proven cardiovascular benefit:
| Medication | Trial | Cardiovascular Risk Reduction |
|---|---|---|
| Liraglutide | LEADER | 13% reduction in cardiovascular death |
| Semaglutide | SUSTAIN-6 | 26% reduction in MACE |
| Dulaglutide | REWIND | 12% reduction in MACE |
| Tirzepatide | SURPASS-CVO | Positive results |
MACE = Major Adverse Cardiovascular Events (cardiovascular death, nonfatal MI, nonfatal stroke)
Who Benefits Most?
Patients with:
- Established cardiovascular disease (prior heart attack, stroke)
- High cardiovascular risk (multiple risk factors)
- Chronic kidney disease (some GLP-1s also reduce kidney events)
Who Should Consider GLP-1 Agonists?
The 2025 ADA guidelines recommend GLP-1 agonists for:
| Situation | Recommendation |
|---|---|
| High cardiovascular risk | Preferred add-on to metformin |
| Established ASCVD | Indicated regardless of A1C |
| Chronic kidney disease | Consider (especially if also CVD) |
| Need for weight loss | Preferred over medications causing weight gain |
| BMI ≥ 27 with comorbidity OR ≥ 30 | First-line option with metformin |
Ideal Candidates
You might be a good candidate for GLP-1 agonists if you:
- Have type 2 diabetes not at goal with metformin alone
- Have cardiovascular disease or high cardiovascular risk
- Need to lose weight
- Want to reduce the number of medications you take
- Can afford the cost (or have insurance coverage)
Cost and Access
Pricing (Approximate, varies widely)
| Medication | Monthly Cost (without insurance) |
|---|---|
| Semaglutide (Ozempic) | $800-$1,000 |
| Dulaglutide (Trulicity) | $700-$900 |
| Liraglutide (Victoza) | $800-$1,000 |
| Tirzepatide (Mounjaro) | $900-$1,200 |
| Semaglutide oral (Rybelsus) | $800-$1,000 |
Insurance Coverage
- Most Medicare Part D plans cover GLP-1 agonists for diabetes
- Commercial insurance coverage varies
- Prior authorization often required
- Step therapy may be required (try metformin/SGLT2 first)
Cost-Saving Options
- Manufacturer coupons (often reduce copay to $25-$50)
- Patient assistance programs for low-income patients
- Online coupons from manufacturer websites
Practical Considerations
Storage
- Refrigerate unopened pens
- Room temperature okay for opened pens (check specific product)
- Don't freeze
- Discard after expiration date (usually 56 days after opening)
Injection Technique
- Subcutaneous injection (into fatty tissue)
- Common sites: Abdomen (avoid 2 inches around navel), thigh, upper arm
- Rotate injection sites to prevent lipodystrophy
- Pen devices make injection easy (no needle visible)
Timing
- Weekly injections: Same day each week (pick a memorable day)
- Daily injections: Same time each day
- Can be taken with or without food
Key Takeaways
- GLP-1 agonists lower A1C 1.0-2.6% and cause 5-15+ kg weight loss
- Cardiovascular benefit proven for most GLP-1 agonists
- Tirzepatide is most effective for A1C and weight loss
- Side effects are mostly GI and improve over time
- Cost can be a barrier—check insurance coverage and manufacturer programs
- Weekly injections offer convenience and better adherence than daily
FAQ Section
What is the difference between Ozempic and Wegovy?
Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (max dose 2 mg). Wegovy is FDA-approved for weight management (max dose 2.4 mg). The medication is identical; the difference is the approved dose and indication.
Do GLP-1 agonists cause weight loss?
Yes, GLP-1 agonists cause significant weight loss (5-15+ kg depending on the specific medication). The weight loss occurs through reduced appetite, increased fullness, and slowed stomach emptying.
How long do GLP-1 side effects last?
Most GI side effects (nausea, vomiting, diarrhea) occur during dose titration and improve within 4-8 weeks as your body adjusts. Starting at a low dose and increasing gradually minimizes side effects.
Can you stop GLP-1 agonists?
Yes, you can stop GLP-1 agonists, but be aware that blood sugar may increase and weight may be regained. Work with your healthcare provider to transition to alternative medications if needed.
Are GLP-1 agonists safe long-term?
GLP-1 agonists have been used since 2005 (exenatide) and have established long-term safety profiles. Ongoing studies continue to monitor long-term effects. The cardiovascular outcome trials included thousands of patients followed for 3-5 years.
Sources:
- American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1)
- SUSTAIN-6, LEADER, REWIND, SURPASS trials
- ADA GLP-1 Information